Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone cream for persistent hypogonadism after prostate cancer radiotherapy and ADT
ACTRN12625001239459Phase 3Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Hypoandrogenism (TD) comparing Testosterone cream with Placebo cream (2 arms). Primary endpoint: Change in mean serum testosterone from 8-hour sampling at 6 weeks compared with baseline. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
testosterone
03
Conditions
Hypoandrogenism (TD)
Beyond the preview
Go deeper on ACTRN12625001239459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001239459.